HIGHLIGHTS
- What: The authors present an overview of DRUP, illuminating implications for the future. The study team assesses each case submission by aiming to match a specific molecular alteration with an available therapy in DRUP. The article reported the results of 139 patients with various tumor types, either enrolled in DRUP or the Australian Cancer Molecular Screening and Therapeutic (MoST) trial, that were treated with one of the CDK4/6 inhibitors palbociclib or ribociclib as monotherapy, based on complete loss of CDKN2A or SMARCA4 or amplifications of CDK4, CDK6, CCND1, CCND2, or CCND3. While the primary goal is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.